Senores Pharmaceuticals expects to scale its revenue to ₹2,500-3,000 crore over the next three to five years as it expands manufacturing capacity in India and the US and commercialises new products from its approved pipeline. Managing Director Swapnil Shah said the company plans to add a fourth commercial manufacturing line in the US within 12-15 months, while its Atlanta sterile injections facility remains on track for commercialisation over the next 12-18 months.
No articles in the last 24 hours. Expand to 1 week
